About Altor

Altor BioScience is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer and viral infections, based on its engineered cytokine technology platforms.

Our History

Altor was formed in 2002 as a spin-off from Sunol Molecular Corporation (“Sunol”), and is backed by leading venture capital funds, including Sanderling Ventures and TVM Capital. The Company has two proprietary technology platforms: the STAR™ platform and the IL-15 Superagonist platform.